Free Trial
NASDAQ:IMMX

Immix Biopharma (IMMX) Stock Price, News & Analysis

Immix Biopharma logo
$2.11 +0.05 (+2.43%)
As of 05/19/2025 04:00 PM Eastern

About Immix Biopharma Stock (NASDAQ:IMMX)

Key Stats

Today's Range
$2.02
$2.15
50-Day Range
$1.36
$2.14
52-Week Range
$1.26
$2.71
Volume
100,732 shs
Average Volume
122,087 shs
Market Capitalization
$58.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

IMMX MarketRank™: 

Immix Biopharma scored higher than 40% of companies evaluated by MarketBeat, and ranked 671st out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immix Biopharma has received no research coverage in the past 90 days.

  • Read more about Immix Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Immix Biopharma are expected to grow in the coming year, from ($0.87) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immix Biopharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immix Biopharma is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immix Biopharma has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.33% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently increased by 15.63%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immix Biopharma does not currently pay a dividend.

  • Dividend Growth

    Immix Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.33% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently increased by 15.63%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Immix Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for IMMX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immix Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    55.40% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.26% of the stock of Immix Biopharma is held by institutions.

  • Read more about Immix Biopharma's insider trading history.
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

IMMX Stock News Headlines

How I profit during chaos…
This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. In the first quarter of this year, in one of the most volatile markets in history, he used his time-tested strategy to go 12 for 12. That's a 100% win–rate — while the rest of the world panics.
See More Headlines

IMMX Stock Analysis - Frequently Asked Questions

Immix Biopharma's stock was trading at $2.20 at the beginning of the year. Since then, IMMX shares have decreased by 4.1% and is now trading at $2.11.
View the best growth stocks for 2025 here
.

Immix Biopharma, Inc. (NASDAQ:IMMX) announced its quarterly earnings results on Monday, March, 24th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09.

Immix Biopharma (IMMX) raised $23 million in an IPO on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

Top institutional shareholders of Immix Biopharma include Tocqueville Asset Management L.P. (0.11%). Insiders that own company stock include Ilya M Rachman, Sean Senn, Jason Hsu, Gabriel S Morris, Carey Ng, Helen C Adams and Magda Marquet.
View institutional ownership trends
.

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

Last Earnings
3/24/2025
Today
5/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMMX
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+231.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.81 per share
Price / Book
2.60

Miscellaneous

Free Float
14,057,000
Market Cap
$58.82 million
Optionable
Optionable
Beta
0.27
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:IMMX) was last updated on 5/20/2025 by MarketBeat.com Staff
From Our Partners